A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant Fusion (F) nanoparticle vaccine in healthy women of childbearing age

Journal of Infectious Diseases

Volumn 213, Issue 3, 2016, Pages 411-422

  Glenn, Gregory M ^a   Fries, Louis F ^a   Thomas, D Nigel ^a   Smith, Gale ^a   Kpamegan, Eloi ^a   Lu, Hanxin ^a   Flyer, David ^a   Jani, Dewal ^a   Hickman, Somia P ^a   Piedra, Pedro A ^b  

^a NOVAVAX INC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

anti F IgG; F or fusion protein; microneutralization; nanoparticle vaccine; palivizumab competitive antibody (PCA); recombinant; respiratory syncytial virus (RSV)

Indexed keywords

ALUMINUM PHOSPHATE; ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PALIVIZUMAB COMPETING ANTIBODY; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS RECOMBINANT FUSION NANOPARTICLE VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; VIRUS ANTIBODY; VIRUS VACCINE;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHILL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS A; HUMAN RESPIRATORY SYNCYTIAL VIRUS B; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE REACTION; MATERNAL IMMUNIZATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEROCONVERSION; SINGLE DRUG DOSE; UNITED STATES; ADOLESCENT; BLOOD; DOSE RESPONSE; IMMUNOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STANDARDS; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; NANOPARTICLES; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL VACCINES; YOUNG ADULT;

EID: 84960354838     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv406     Document Type: Article

References (36)

1. Nair H, Nokes DJ, Gessner BD,. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-Analysis. Lancet 2010; 375: 1545-55.
2. Stockman LJ, Curns AT, Anderson LJ,. et al. Respiratory syncytial virus-Associated hospitalizations among infants and young children in the United States, 1997- 2006. Pediatr Infect Dis J 2012; 31: 5-9.
3. Centers for Disease Control and Prevention. update May 05, 2015. Respiratory Syncytial Virus Infection. Trends and Surveillance. http: //www.cdc.gov/rsv/ research/us-surveillance.html. Accessed 5 May 2015.
4. Boyce TG, Mellen BG, Mitchel EF Jr,. et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137: 865-70.
5. Glezen WP, Taber LH, Frank AL,. et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140: 543-6.
6. Beeler JA, Van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989; 63: 2941-50.
7. Swanson KA, Settembre EC, Shaw CA,. et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 2011; 108: 9619-24.
8. Tapia LI, Shaw CA, Aideyan LO,. et al. Gene sequence variability of the three surface proteins of human respiratory syncytial virus (HRSV) in Texas. PLOS One 2014; 9: e90786.
9. Groothuis JR, Hoopes JM, Hemming VG. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther 2011; 28: 110-25.
10. Feltes TF, Sondheimer HM, Tulloh RM,. et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011; 70: 186-91.
11. Carbonell-Estrany X, Simoes EA, Dagan R,. et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010; 125: e35-51.
12. Glenn GM, Smith G, Fries L,. et al. Safety and immunogenicity of a Sf9 insect cellderived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013; 31: 524-32.
13. Smith G, Raghunandan R, Wu Y,. et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLOS One 2012; 7: e50852.
14. Piedra PA, Jewell AM, Cron SG,. et al. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003; 21: 3479-82.
15. Piedra PA, Glezen WP, Kasel JA,. et al. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine 1995; 13: 1095-101.
16. Kpamegan E, Zheng L. Concordance between laboratories testing clinical samples and its impact on vaccine booster thresholds. J Stat Sci Appl 2014; 2: 55-62.
17. Suara RO, Piedra PA, Glezen WP,. et al. Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in the United States. Clin Diagn Lab Immunol 1996; 3: 477-9.
18. Chu HY, Steinhoff MC, Magaret A,. et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis 2014; 210: 1582-9.
19. Shinoff JJ, O'Brien KL, Thumar B,. et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis 2008; 198: 1007-15.
20. Falsey AR, McElhaney JE, Beran J,. et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis 2014; 12: 1873-81.
21. Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 2006; 78: 1493-7.
22. Johnson S, Oliver C, Prince GA,. et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176: 1215-24.
23. Huang K, Incognito L, Cheng X,. et al. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol 2010; 84: 8132-40.
24. Lu H, Raghunandan R, Flyer D,. et al. Development and characterization of recombinant RSV F nanoparticle vaccine induced monoclonal antibody. In: Programs and Abstracts of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2014.
25. Khan AA, Zahidie A, Rabbani F. Interventions to reduce neonatal mortality from neonatal tetanus in low and middle income countries-A systematic review. BMC Public Health 2013; 13: 322.
26. Pasternak B, Svanstrom H, Molgaard-Nielsen D,. et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA 2012; 308: 165-74.
27. Richards JL, Hansen C, Bredfeldt C,. et al. Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth. Clin Infect Dis 2013; 56: 1216-22.
28. Steinhoff MC, Omer SB, Roy E,. et al. Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial. CMAJ 2012; 184: 645-53.
29. Zaman K, Roy E, Arifeen SE,. et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359: 1555-64.
30. Palmeira P, Quinello C, Silveira-Lessa AL,. et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; doi: 10.1155/ 2012/985646.
31. Lindsey B, Kampmann B, Jones C. Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants. Curr Opin Infect Dis 2013; 26: 248-53.
32. Van den Berg JP, Westerbeek EA, Van Der Klis FR,. et al. Transplacental transport of IgG antibodies to preterm infants: a review of the literature. Early Hum Dev 2011; 87: 67-72.
33. O'Shea MK, Pipkin C, Cane PA,. et al. Respiratory syncytial virus: an important cause of acute respiratory illness among young adults undergoing military training. Influenza Other Respir Viruses 2007; 1: 193-7.
34. Raghunandan R, Lu H, Zhou B,. et al. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine 2014; 32: 6485-92.
35. Lagos R, DeVincenzo JP, Munoz A,. et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J 2009; 28: 835-7.
36. O'Shea MK, Ryan MA, Hawksworth AW,. et al. Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment. Clin Infect Dis 2005; 41: 311-7.